6-12-2025, 10:11

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Notified -
Globe Newswire6-12-2025, 10:11
25-11-2025, 08:24

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

Notified -
Globe Newswire25-11-2025, 08:24
25-04-2025, 18:43

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

Notified -
Globe Newswire25-04-2025, 18:43
27-03-2025, 08:00

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

Notified -
Globe Newswire27-03-2025, 08:00